Johannes David Smeijer
7PUBLICATIONS
16CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (7)
Sort by Publication Date:
|May 21, 2025
Effects of combined treatment with zibotentan and dapagliflozin compared to dapagliflozin alone in patients with diabetic and non-diabetic chronic kidney disease.Victor Wasehuus, J David Smeijer, Phil Ambery
|Jan 10, 2025
Authors' Reply: Effects of Zibotentan and Dapagliflozin on Fluid Retention in Patients with CKD: Need More Evidence.Hiddo J L Heerspink, Johannes David Smeijer
|Dec 11, 2024
Sex differences in response to the endothelin receptor antagonist atrasentan in individuals with type 2 diabetes and chronic kidney disease: a post hoc analysis of the SONAR trial.J David Smeijer, Sieta T de Vries, Donald E Kohan
|Nov 06, 2024
The effect of the endothelin receptor antagonist atrasentan on insulin resistance in phenotypic clusters of patients with type 2 diabetes and chronic kidney disease.Johannes David Smeijer, Maria F Gomez, Peter Rossing
|Oct 01, 2024
Effects of Zibotentan Alone and in Combination with Dapagliflozin on Fluid Retention in Patients with CKD.J David Smeijer, Victor S Wasehuus, Neeraj Dhaun
|May 09, 2023
Diuretic medication and change in fluid retention biomarkers during treatment with the endothelin receptor antagonist atrasentan.J David Smeijer, Donald E Kohan, Dick de Zeeuw
Pageof 2
Frequent Collaborators
6 joint publications
Hiddo J L Heerspink
3 joint publications
Donald E Kohan
2 joint publications
Fan-Fan Hou
2 joint publications
Victor Wasehuus
2 joint publications
Peter Rossing
2 joint publications
Phil Ambery
1 joint publications
Jeroen V Koomen
1 joint publications
George L Bakris
1 joint publications
Michal Nowicki
1 joint publications
Neeraj Dhaun
